International Searching and Preliminary Examining Authorities

IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals

Friday, March 27, 2020 - 12:30am

IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016.

Key Points: 
  • IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016.
  • A public copy of the patent is available on the USPTO website.
  • A patent for an invention is the grant of a property right to the inventor, issued by the USPTO.
  • The company is based in Maryland, U.S.A. Our website: www.igcinc.us .Twitter @IGCIR
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005803/en/

SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039

Wednesday, March 18, 2020 - 10:30am

The 087 patent is a composition of matter patent that covers the polymorphic form of nirogacestat that is currently in clinical development.

Key Points: 
  • The 087 patent is a composition of matter patent that covers the polymorphic form of nirogacestat that is currently in clinical development.
  • SpringWorks has exclusive rights to the 087 patent pursuant to an existing worldwide license with Pfizer.
  • We are very pleased that the USPTO has issued this patent, which builds upon our existing intellectual property portfolio and extends patent protection for nirogacestat to 2039, said Saqib Islam, Chief Executive Officer of SpringWorks.
  • In addition, SpringWorks is seeking to advance nirogacestat as a cornerstone of B-cell maturation antigen (BCMA) combination therapy in multiple myeloma.

United States Patent & Trademark Office (USPTO) hosting a job fair in Atlanta, GA on February 21st - February 22nd, where USPTO is hiring hundreds of new examiners in 2020

Saturday, February 15, 2020 - 4:45pm

The USPTO is hiring 100s of engineers to examine America's patents in 2020!

Key Points: 
  • The USPTO is hiring 100s of engineers to examine America's patents in 2020!
  • Even more positions will be opening up in the agency's Rocky Mountain regional office in Denver later in the year.
  • Patent examination is a mission-critical component of the intellectual property ecosystem and the agency's efforts to safeguard American ingenuity.
  • Our examiners work closely with entrepreneurs to process their patent applications and determine whether or not a patent can be granted.

No Borders, Inc. (Ticker: NBDR) Announces Blockchain Patent Filing With the USPTO

Tuesday, February 4, 2020 - 2:19pm

This provisional patent, registered as Application Serial #62969531 with the USPTO on Feb. 3, 2020, now allows the Companys CBD LabChain platform to operate with Patent Pending identifiers and messaging.

Key Points: 
  • This provisional patent, registered as Application Serial #62969531 with the USPTO on Feb. 3, 2020, now allows the Companys CBD LabChain platform to operate with Patent Pending identifiers and messaging.
  • The Provisional Patent for CBD LabChain was filed with the title:
    No Borders, Inc. CEO Joseph Snyder stated, It has been a long road to get to this day and I am stoked to share our first patent filing with the world!
  • This filing marks a milestone for our Company and our amazing shareholders.
  • No Borders Naturals now certifies 100% ofits products and their efficacy via the Companys breakthrough CBD LabChain Certification Platform.

Auris Medical Announces Notice of Allowance for European Patent Application

Friday, January 10, 2020 - 1:30pm

Hamilton, Bermuda, January 10, 2020 Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the European Patent Office (EPO) has issued a notice of Intention to Grant for its patent application entitled Treatment of Tinnitus Through Modulation of Chloride Co-Transporter NKCC1 in the Auditory System (European Patent Application 11 894 529.3).

Key Points: 
  • Hamilton, Bermuda, January 10, 2020 Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the European Patent Office (EPO) has issued a notice of Intention to Grant for its patent application entitled Treatment of Tinnitus Through Modulation of Chloride Co-Transporter NKCC1 in the Auditory System (European Patent Application 11 894 529.3).
  • The communication from the EPO concludes substantive examination of the patent application, which is now expected to issue as a patent once the issue fees are paid and the patent office concludes its respective administrative procedures.
  • A corresponding patent application is currently pending before the US Patent and Trademark Office (USPTO) and was already granted in Japan.
  • Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders.

IP Litigation Duo Rejoins Bracewell in Austin as Texas Becomes Increasingly Popular Jurisdiction for Patent Disputes

Monday, December 9, 2019 - 3:00pm

"They are exceptional litigators who are highly regarded in the IP and Texas legal communities, and their addition will strengthen our firm-wide IP litigation practice."

Key Points: 
  • "They are exceptional litigators who are highly regarded in the IP and Texas legal communities, and their addition will strengthen our firm-wide IP litigation practice."
  • Chibib has a broad IP litigation practice that includes representing companies in the semiconductor, telecommunications, electronics and software fields.
  • Chibib also has an active post-grant practice before the US Patent and Trademark Office's (USPTO) Patent Trial and Appeal Board.
  • This includes patent litigation, trademark and trade secret disputes, as well as disputes involving breach of contract, fraud, unfair competition and breach of fiduciary duty.

South Korean VR Firm Moiin Group Receives Patent for Digital Identity

Thursday, November 7, 2019 - 11:15am

SEOUL, South Korea, Nov. 7, 2019 /PRNewswire/-- Moiin Group is pleased to announce that they have been awarded a patent for the protection of VR identities.

Key Points: 
  • SEOUL, South Korea, Nov. 7, 2019 /PRNewswire/-- Moiin Group is pleased to announce that they have been awarded a patent for the protection of VR identities.
  • This patent permits them to grant users ownership of their own identities and create protected and unique avatars within the Oasis City platform.
  • Recorded by the Korean Intellectual Property Office (KIPO) as Patent #420010305761, this patent becomes one of many currently held by the Moiin Group, covering everything from the hardware designed to be used with the Oasis City ecosystem to pieces of software performing tasks that make Oasis City a possibility.
  • Moiin Group expects users to have access to technology shortly after the release of the first version of the Oasis City software, scheduledin 2020.

IRLAB's Drug Candidates IRL942 and IRL1009 Have Been Granted Patents in the US and Europe

Wednesday, November 6, 2019 - 9:58am

STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- IRLAB announced today that drug candidates IRL942 and IRL1009 have been granted composition of matter patents in the US and Europe from respective authorities.

Key Points: 
  • STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- IRLAB announced today that drug candidates IRL942 and IRL1009 have been granted composition of matter patents in the US and Europe from respective authorities.
  • The preclinical drug candidates are currently undergoing preparatory steps to meet the regulatory requirements for obtaining permission to conduct clinical phase I studies.
  • Drug candidates IRL942 and IRL1009 stem from IRLAB's P001 research program and are derived from the proprietary research platform ISP.
  • The US Patent and Trademark Office (USPTO) and its counterpart the European Patent Office (EPO) are the authorities having granted patents for the drug candidates IRL942 and IRL1009.

IRLAB's Drug Candidates IRL942 and IRL1009 Have Been Granted Patents in the US and Europe

Wednesday, November 6, 2019 - 9:53am

STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- IRLAB announced today that drug candidates IRL942 and IRL1009 have been granted composition of matter patents in the US and Europe from respective authorities.

Key Points: 
  • STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- IRLAB announced today that drug candidates IRL942 and IRL1009 have been granted composition of matter patents in the US and Europe from respective authorities.
  • The preclinical drug candidates are currently undergoing preparatory steps to meet the regulatory requirements for obtaining permission to conduct clinical phase I studies.
  • Drug candidates IRL942 and IRL1009 stem from IRLAB's P001 research program and are derived from the proprietary research platform ISP.
  • The US Patent and Trademark Office (USPTO) and its counterpart the European Patent Office (EPO) are the authorities having granted patents for the drug candidates IRL942 and IRL1009.

Guardion® Receives approval from USPTO for expanded claims for its Proprietary Medical Device, the MAPCAT SF

Wednesday, October 23, 2019 - 12:00pm

San Diego, California, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Guardion or the Company) (Nasdaq: GHSI) announced that it has received approval from the USPTO for additional claims reflected in a new patent for its proprietary medical device, the MapcatSF.

Key Points: 
  • San Diego, California, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Guardion or the Company) (Nasdaq: GHSI) announced that it has received approval from the USPTO for additional claims reflected in a new patent for its proprietary medical device, the MapcatSF.
  • Michael Favish, Guardions Chief Executive Officer, commenting on the granting of this expanded patent stated, The approval of these claims to our existing patent strengthens our patent for both domestic and international protection.
  • Guardion has also developed a proprietary medical device, the MapcatSF, which accurately measures the macular pigment density, therefore providing the only two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment.
  • Guardion has completed development of the proprietary VectorVision CSV-2000 standardized contrast sensitivity test and recently introduced the commercial product to the marketplace.